Fibroblast growth factor (FGF), FGF receptor (FGFR), and cyclin D1 (CCND1) DNA methylation in head and neck squamous cell carcinomas is associated with transcriptional activity, gene amplification, human papillomavirus (HPV) status, and sensitivity to tyrosine kinase inhibitors.
Carcinoma, Squamous Cell
/ epidemiology
Cohort Studies
Cyclin D1
/ analysis
DNA Methylation
/ genetics
Fibroblast Growth Factors
/ analysis
Head and Neck Neoplasms
/ epidemiology
Humans
Papillomavirus Infections
/ complications
Protein-Tyrosine Kinases
/ drug effects
Receptors, Fibroblast Growth Factor
/ drug effects
Statistics, Nonparametric
Cyclin D1 (CCND1)
DNA methylation
Fibroblast growth factor (FGF)
Fibroblast growth factor receptor (FGFR)
Head and neck squamous cell carcinoma (HNSCC)
Human papillomavirus (HPV)
Predictive biomarker
Tyrosine kinase inhibitor (TKI)
Journal
Clinical epigenetics
ISSN: 1868-7083
Titre abrégé: Clin Epigenetics
Pays: Germany
ID NLM: 101516977
Informations de publication
Date de publication:
21 12 2021
21 12 2021
Historique:
received:
11
05
2021
accepted:
08
12
2021
entrez:
22
12
2021
pubmed:
23
12
2021
medline:
1
2
2022
Statut:
epublish
Résumé
Dysregulation of fibroblast growth factor receptor (FGFR) signaling pathway has been observed in head and neck squamous cell carcinoma (HNSCC) and is a promising therapeutic target for selective tyrosine kinase inhibitors (TKIs). Potential predictive biomarkers for response to FGFR-targeted therapies are urgently needed. Understanding the epigenetic regulation of FGF pathway related genes, i.e. FGFRs, FGFs, and CCND1, could enlighten the way towards biomarker-selected FGFR-targeted therapies. We performed DNA methylation analysis of the encoding genes FGFR1, FGFR2, FGFR3, FGFR4, FGF1-14, FGF16-23, and CCND1 at single CpG site resolution (840 CpG sites) employing The Cancer Genome Research Atlas (TCGA) HNSCC cohort comprising N = 530 tumor tissue and N = 50 normal adjacent tissue samples. We correlated DNA methylation to mRNA expression with regard to human papilloma virus (HPV) and gene amplification status. Moreover, we investigated the correlation of methylation with sensitivity to the selective FGFR inhibitors PD 173074 and AZD4547 in N = 40 HPV(-) HNSCC cell lines. We found sequence-contextually nuanced CpG methylation patterns in concordance with epigenetically regulated genes. High methylation levels were predominantly found in the promoter flank and gene body region, while low methylation levels were present in the central promoter region for most of the analyzed CpG sites. FGFRs, FGFs, and CCND1 methylation differed significantly between tumor and normal adjacent tissue and was associated with HPV and gene amplification status. CCND1 promoter methylation correlated with CCND1 amplification. For most of the analyzed CpG sites, methylation levels correlated to mRNA expression in tumor tissue. Furthermore, we found significant correlations of DNA methylation of specific CpG sites with response to the FGFR1/3-selective inhibitors PD 173074 and AZD4547, predominantly within the transcription start site of CCND1. Our results suggest an epigenetic regulation of CCND1, FGFRs, and FGFs via DNA methylation in HNSCC and warrants further investigation of DNA methylation as a potential predictive biomarker for response to selective FGFR inhibitors in clinical trials.
Sections du résumé
BACKGROUND
Dysregulation of fibroblast growth factor receptor (FGFR) signaling pathway has been observed in head and neck squamous cell carcinoma (HNSCC) and is a promising therapeutic target for selective tyrosine kinase inhibitors (TKIs). Potential predictive biomarkers for response to FGFR-targeted therapies are urgently needed. Understanding the epigenetic regulation of FGF pathway related genes, i.e. FGFRs, FGFs, and CCND1, could enlighten the way towards biomarker-selected FGFR-targeted therapies.
METHODS
We performed DNA methylation analysis of the encoding genes FGFR1, FGFR2, FGFR3, FGFR4, FGF1-14, FGF16-23, and CCND1 at single CpG site resolution (840 CpG sites) employing The Cancer Genome Research Atlas (TCGA) HNSCC cohort comprising N = 530 tumor tissue and N = 50 normal adjacent tissue samples. We correlated DNA methylation to mRNA expression with regard to human papilloma virus (HPV) and gene amplification status. Moreover, we investigated the correlation of methylation with sensitivity to the selective FGFR inhibitors PD 173074 and AZD4547 in N = 40 HPV(-) HNSCC cell lines.
RESULTS
We found sequence-contextually nuanced CpG methylation patterns in concordance with epigenetically regulated genes. High methylation levels were predominantly found in the promoter flank and gene body region, while low methylation levels were present in the central promoter region for most of the analyzed CpG sites. FGFRs, FGFs, and CCND1 methylation differed significantly between tumor and normal adjacent tissue and was associated with HPV and gene amplification status. CCND1 promoter methylation correlated with CCND1 amplification. For most of the analyzed CpG sites, methylation levels correlated to mRNA expression in tumor tissue. Furthermore, we found significant correlations of DNA methylation of specific CpG sites with response to the FGFR1/3-selective inhibitors PD 173074 and AZD4547, predominantly within the transcription start site of CCND1.
CONCLUSIONS
Our results suggest an epigenetic regulation of CCND1, FGFRs, and FGFs via DNA methylation in HNSCC and warrants further investigation of DNA methylation as a potential predictive biomarker for response to selective FGFR inhibitors in clinical trials.
Identifiants
pubmed: 34933671
doi: 10.1186/s13148-021-01212-4
pii: 10.1186/s13148-021-01212-4
pmc: PMC8693503
doi:
Substances chimiques
CCND1 protein, human
0
Receptors, Fibroblast Growth Factor
0
Cyclin D1
136601-57-5
Fibroblast Growth Factors
62031-54-3
Protein-Tyrosine Kinases
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
228Subventions
Organisme : University Medical Center Bonn (UKB)
ID : O-138.0008
Informations de copyright
© 2021. The Author(s).
Références
Genome Res. 2002 Mar;12(3):458-61
pubmed: 11875034
Genes Dev. 1993 May;7(5):812-21
pubmed: 8491378
Nucleic Acids Res. 2019 Jan 8;47(D1):D711-D715
pubmed: 30357387
N Engl J Med. 2019 Jul 25;381(4):338-348
pubmed: 31340094
Epigenetics Chromatin. 2015 Apr 17;8:14
pubmed: 25960768
Epigenetics. 2007 Jan-Mar;2(1):54-65
pubmed: 17965591
CA Cancer J Clin. 2010 Nov-Dec;60(6):376-92
pubmed: 20959400
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Nucleic Acids Res. 2000 May 15;28(10):2108-13
pubmed: 10773079
J Med Chem. 1997 Jul 18;40(15):2296-303
pubmed: 9240345
Trends Genet. 2004 Nov;20(11):563-9
pubmed: 15475116
Ann Oncol. 2018 Dec 1;29(12):2313-2327
pubmed: 30307465
Am J Epidemiol. 2013 Sep 1;178(5):679-90
pubmed: 23817919
Cancer Metastasis Rev. 2017 Sep;36(3):411-423
pubmed: 28801840
Nature. 2015 Jan 29;517(7536):576-82
pubmed: 25631445
BMC Cancer. 2020 Apr 18;20(1):348
pubmed: 32326908
Nat Rev Cancer. 2017 May;17(5):318-332
pubmed: 28303906
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
J Clin Oncol. 2018 Jan 20;36(3):276-282
pubmed: 29182496
J Natl Compr Canc Netw. 2017 Dec;15(12):1456-1459
pubmed: 29223982
J Cancer Res Clin Oncol. 2020 Jul;146(7):1677-1692
pubmed: 32372145
Cell. 2010 Jun 25;141(7):1117-34
pubmed: 20602996
Eur J Cancer. 2015 Oct;51(15):2130-2143
pubmed: 26421817
Epigenetics Chromatin. 2018 Jun 29;11(1):37
pubmed: 29958539
N Engl J Med. 2005 Mar 10;352(10):997-1003
pubmed: 15758010
JCO Precis Oncol. 2018;2:
pubmed: 31123723
Cancer. 2016 Oct;122(19):3024-31
pubmed: 27315356
Oncogene. 2004 Apr 29;23(20):3501-8
pubmed: 15116089
Head Neck. 2016 Apr;38 Suppl 1:E1646-52
pubmed: 26849095
Biostatistics. 2010 Jan;11(1):164-75
pubmed: 19837654
Nucleic Acids Res. 2021 Jan 8;49(D1):D884-D891
pubmed: 33137190
BMC Cancer. 2011 Mar 22;11:102
pubmed: 21426551
EBioMedicine. 2017 Mar;17:223-236
pubmed: 28314692
Int J Mol Sci. 2014 Aug 08;15(8):13768-801
pubmed: 25110867
N Engl J Med. 2010 Jul 1;363(1):24-35
pubmed: 20530316
BMC Cancer. 2016 Sep 23;16(1):749
pubmed: 27663357
J Cancer Res Clin Oncol. 2018 Jan;144(1):53-61
pubmed: 29022097
Clin Cancer Res. 2009 Jul 1;15(13):4431-8
pubmed: 19549773
Cells. 2019 Jun 18;8(6):
pubmed: 31216761
Biomed Res Int. 2020 Jun 3;2020:5658904
pubmed: 32596330
Clin Cancer Res. 2015 Oct 1;21(19):4356-64
pubmed: 26015511
Cancer Res. 2002 Apr 15;62(8):2378-84
pubmed: 11956100
Clin Cancer Res. 2016 Aug 1;22(15):3884-93
pubmed: 26936917
J Clin Oncol. 2020 Jul 20;38(21):2407-2417
pubmed: 32463741
Lancet Oncol. 2019 Oct;20(10):1454-1466
pubmed: 31405822
Nat Genet. 2011 Nov 27;44(1):40-6
pubmed: 22120008
J Clin Pathol. 2006 May;59(5):445-53
pubmed: 16644882
Adv Exp Med Biol. 2016;879:71-90
pubmed: 26659264
EMBO J. 1998 Oct 15;17(20):5896-904
pubmed: 9774334
Cell. 2013 Mar 28;153(1):38-55
pubmed: 23540689
J Biol Chem. 2003 Sep 5;278(36):34226-36
pubmed: 12815063
Genome Biol. 2015 Mar 24;16:56
pubmed: 25887522
Cold Spring Harb Perspect Biol. 2013 Jun 01;5(6):
pubmed: 23732477
Oncologist. 2010;15(9):994-1001
pubmed: 20798198
Cell Commun Signal. 2020 Jan 27;18(1):13
pubmed: 31987043
Cancers (Basel). 2020 Mar 26;12(4):
pubmed: 32224897
Sci Rep. 2017 Dec 1;7(1):16715
pubmed: 29196639
Int J Mol Sci. 2018 Jun 26;19(7):
pubmed: 29949887
Genome Med. 2013 Feb 05;5(2):15
pubmed: 23419152
J Biol Chem. 2004 Nov 26;279(48):50004-11
pubmed: 15377668
J Med Microbiol. 2019 Mar;68(3):440-445
pubmed: 30624179
Nat Rev Genet. 2012 May 29;13(7):484-92
pubmed: 22641018
Sci Transl Med. 2010 Dec 15;2(62):62ra93
pubmed: 21160078
Cancer Res. 2012 Apr 15;72(8):2045-56
pubmed: 22369928